| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8778532 | European Urology | 2018 | 9 Pages |
Abstract
Updated Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial findings show that radium-223 remained well tolerated during treatment and up to 3 yr after each patient's first injection.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Christopher C. Parker, Robert E. Coleman, Oliver Sartor, Nicholas J. Vogelzang, David Bottomley, Daniel Heinrich, Svein I. Helle, Joe M. O'Sullivan, Sophie D. Fosså, Aleš Chodacki, PaweŠWiechno, John Logue, Mihalj Seke, Anders Widmark,